Uranium Royalty Corp. Common Stock

UROY

Uranium Royalty Corp. (UROY) is a royalty and streaming company focused on acquiring and managing interests in uranium properties and projects. It aims to generate income from royalties and streams on uranium production and development assets worldwide, providing investors exposure to the uranium market without direct operational involvement.

$4.64 +0.03 (0.65%)
🚫 Uranium Royalty Corp. Common Stock does not pay dividends

Company News

Oklo And Other Nuclear Stocks — Powered By The Department Of Energy
Benzinga • Erica Kollmann • October 15, 2025

The Department of Energy launched a Defense Production Act Consortium to reinvigorate the U.S. nuclear fuel cycle, bringing together nuclear companies and partners to reduce foreign uranium dependence and accelerate nuclear reactor projects.

Uranium Royalty Corp. Acquires Royalty on Forum Energy Metals Aberdeen Uranium Project in Canada
Benzinga • Prnewswire • May 27, 2025

Uranium Royalty Corp. has acquired a 2.0% gross overriding royalty on the Aberdeen Uranium Project operated by Forum Energy Metals in Nunavut, Canada for CAD$1 million. The project is located adjacent to Orano's Kiggavik project, one of the largest undeveloped uranium projects globally.

Uranium Royalty: The Cheapest Setup In Its History
Seeking Alpha • Trapping Value • June 4, 2024

Uranium Royalty has generally traded quite expensive relative to its potential. Read more to see our recommendation on UROY stock.

The ‘nuclear renaissance’ is upon us. What investors need to know about uranium.
MarketWatch • MarketWatch • March 5, 2024

The rally in uranium prices is drawing investor attention to what one analyst calls a ‘renaissance’ for nuclear power.

PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
Benzinga • Lisa Levin • October 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. Akero Therapeutics, Inc. (NASDAQ: AKRO) shares dipped 63.9% to $17.52 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead prod...

Related Companies